CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC)

PHASE2UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 18, 2019

Primary Completion Date

June 30, 2021

Study Completion Date

December 31, 2021

Conditions
Small Cell Lung Cancer
Interventions
DRUG

CM082 plus JS001

CM082: 150mg once a day orally (taken within half an hour after breakfast) JS001: An intravenous infusion of a solution having a concentration of 1-3mg/ml was prepared with 0.9% physiological saline, and administered once every three weeks. Using an inline filter (0.2 or 0.22 μm), the drug was diluted with physiological saline and intravenously administered within 60 minutes.

Trial Locations (2)

Unknown

NOT_YET_RECRUITING

National Cancer Center/Cancer Hospital, Beijing

RECRUITING

The First Hospital of China Medical University, Shenyang

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AnewPharma

INDUSTRY

NCT03904719 - CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC) | Biotech Hunter | Biotech Hunter